We have changed our name from Cure Our Ovarian Cancer to the Ovarian Cancer Foundation NZ » Read More

Inaugural Low-Grade Serous Ovarian Cancer Symposium

The entrance to the Sylvester Cancer Centre, University of Miami

Low-grade serous ovarian cancer is the fourth most common type of ovarian cancer. It disproportionately affects younger women. There is little research, and survival is poor. Cure Our Ovarian Cancer supports women with this cancer on a global level, providing subtype-specific cancer information and fundraising for research to improve their survival.

In February 2019, over twenty influential researchers gathered to discuss low-grade serous ovarian cancer (LGSOC) in Miami. The meeting was made possible by funding from a patient of Dr Slomovitz from the University of Miami, the Dwoskin Charitable Trust Foundation and the O’Bryan GYN Precision Medical Initiative Fund, and we had the privilege of receiving an invitation.

The conference was an exciting development for low-grade serous ovarian cancer research for several reasons – it was the first-ever meeting focused solely on LGSOC, it brought some of the best and brightest international researchers together, and for many, it was the first time they had met in person.

The LGSOC research community is small. But because of this, it attracts some talented and persistent individuals. Researchers who are primarily motivated by a desire to improve the lives of women with LGSOC. Researchers who are willing to share their knowledge and work together. Researchers who enjoy solving problems.

One researcher summed it up nicely. He said that with some types of cancers, it is easy to be arrogant because the survival rate is already very high, but with low-grade serous ovarian cancer, it is very humbling. You have to constantly think about how you can do things better.

Researchers discussed their latest research findings and strategised promising areas of future research. One particular area of discussion focused on drug combinations. Researchers think adding another medication to existing medication could improve outcomes. Researchers also discussed how to apply recent successes of other cancers to LGSOC.

Another important part of the meeting focused on ways to get more funding. Traditional research funding avenues often focus on impact, which means less common cancers like LGSOC, which affects 1 in 1000 women, are often overlooked. More common cancers with better survival receive a disproportionate share of funding.

Your support can make a difference in the lives of thousands of women. There has been incredible progress in other cancers in recent years; help us help them apply this knowledge to low-grade serous ovarian cancer with life-saving research.

OCFNZ started as Cure Our Ovarian Cancer in 2018, with a focus on low-grade serous ovarian cancer. In 2020, we expanded our focus to include all ovarian cancer and, in 2024, we changed our name to the Ovarian Cancer Foundation New Zealand.